Price Chart

Profile

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
URL https://www.avrobio.com
Investor Relations URL https://investors.avrobio.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 22, 2024 (est.)
Last Earnings Release Nov. 09, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
URL https://www.avrobio.com
Investor Relations URL https://investors.avrobio.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 22, 2024 (est.)
Last Earnings Release Nov. 09, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A